Funding news
Syntax Bio logo

Syntax Bio Raises $14.4M Seed Round

Recently funded · $14.4M SeedHospitals and Health CareUSView source

Get the full Syntax Bio company profile

Access contacts, investors, buying signals & more

Open in Dashboard

Syntax Bio, the synthetic biology company programming the next generation of stem cell-derived therapies and organoids, has raised $14.4M in a seed funding round. The company is developing a new approach to regenerative medicine discovery and manufacturing.

Its proprietary Cellgorithm platform uses a CRISPR-based system to accelerate and scale stem cell differentiation. This technology aims to replace slow, manual processes with a rapid, programmable method that mimics human development, making cell generation faster, more reliable, and accessible for biopharma developers and patients.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Seed rounds

Companies that recently closed a Seed round.

#CompanyAmount
1
Tombot logo

Tombot

United States

$7.0M
2
Tripay logo

Tripay

United States

$52.0K
3
BlueFletch logo

BlueFletch

United States

$225.0K
4
Paralos Bioscience Inc. logo

Paralos Bioscience Inc.

United States

$646.9K
5
Virbela logo

Virbela

$800.0K